ICICI Direct has given Buy recommendation for Torrent Pharmaceuticals with a target price of Rs. 3235 in its research report issued on May 26, 2022

ICICI Direct’s research report on Torrent Pharmaceuticals

Incorporated in 1959, Torrent has a strong presence in domestic and semi-regulated markets and a growing presence in regulated markets. Revenues – India including CRAMs (57%), Brazil (9%), US (13%) and Germany (11%) • Torrent is the eighth largest domestic player and is ranked in top 10 for CVS, CNS, V&M, GI and anti-diabetes therapies in India.


Upgrade from HOLD to BUY due to 1) good traction in branded business with India, Brazil growth prospects looking solid, Valued at Rs 3235 i.e. 30x P/E on FY24E EPS of Rs 107.8.

Leave a Reply

Your email address will not be published.